Repare Therapeutics (NASDAQ:RPTX) Shares Down 1.3% – What’s Next?

Repare Therapeutics Inc. (NASDAQ:RPTX) shares dropped 1.3% during mid-day trading on Friday . The company traded as low as $1.45 and last traded at $1.47. Approximately 129,515 shares traded hands during trading, a decline of 49% from the average daily volume of 253,318 shares. The stock had previously closed at $1.49.

Analysts Set New Price Targets

Separately, HC Wainwright cut their price objective on shares of Repare Therapeutics from $10.00 to $5.00 and set a “buy” rating for the company in a report on Friday, March 7th.

Repare Therapeutics Stock Down 1.3%

The stock has a market capitalization of $63.05 million, a PE ratio of -0.74 and a beta of 0.85. The stock’s 50 day moving average price is $1.26 and its 200-day moving average price is $1.46.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RPTX. Vontobel Holding Ltd. grew its position in shares of Repare Therapeutics by 45.8% in the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock worth $46,000 after buying an additional 11,000 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Repare Therapeutics by 2,144,950.0% in the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company’s stock worth $112,000 after buying an additional 85,798 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Repare Therapeutics by 204.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company’s stock worth $45,000 after buying an additional 23,127 shares during the last quarter. Stifel Financial Corp grew its position in shares of Repare Therapeutics by 73.1% in the 4th quarter. Stifel Financial Corp now owns 89,500 shares of the company’s stock worth $117,000 after buying an additional 37,800 shares during the last quarter. Finally, Blue Owl Capital Holdings LP boosted its stake in Repare Therapeutics by 2.1% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,443,659 shares of the company’s stock worth $4,511,000 after purchasing an additional 71,160 shares in the last quarter. 85.09% of the stock is currently owned by institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.